Alto Neuroscience (ANRO) Earnings Date & Reports

Key Takeaways

• Alto Neuroscience (ANRO) reported a net loss of $25.1 million, or $0.54 per share, for the third quarter ended September 30, 2026, compared with a $14.2 million loss in the prior-year quarter.
• The reported loss per share was narrower than the roughly $0.67 per share loss Wall Street analysts had anticipated, according to consensus estimates.
• Research and development (R&D) expenses climbed to $18.2 million from $10.5 million a year earlier, driven by spending on the ALTO-207 PACE clinical program.
• The company ended the quarter with about $319.8 million in cash, cash equivalents, and restricted cash, which management expects to fund operations through 2030.
• Key pipeline readouts remain on track, including ALTO-300 Phase 2b topline data in the first half of 2027 and ALTO-207 PACE-1 data in the second half of 2027.
• For more on Alto Neuroscience's Major News, Today's Price Move, Price Targets, and Forecast, visit these dedicated pages for additional detail.
• Explore Trending AI Robots to see how AI-driven trading tools are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

Alto Neuroscience is a clinical-stage biopharmaceutical company, meaning it generates no product revenue and investors judge each quarter primarily on spending discipline, cash runway, and the progress of its drug pipeline. The company is advancing treatments for depression, schizophrenia, and other neuropsychiatric conditions using its Precision Psychiatry Platform, which analyzes brain biomarkers such as electroencephalogram (EEG) activity to match patients to the right drug. This third-quarter report matters because it reveals whether Alto can sustain an expanding late-stage development program—led by ALTO-207 in treatment-resistant depression (TRD)—while preserving enough cash to reach critical data readouts over the next two years. The July 2026 financing also reshaped the balance sheet, giving the company a longer runway to execute its clinical strategy.

Reported Results

For the third quarter ended September 30, 2026, Alto Neuroscience reported a net loss of $25.1 million, or $0.54 per basic and diluted share, compared with a net loss of $14.2 million in the same period a year earlier. The per-share loss came in narrower than the roughly $0.67 per share consensus estimate, a modest beat driven by a smaller-than-expected loss.

Operating expenses rose sharply as the pipeline advanced. Research and development (R&D) expense increased to $18.2 million from $10.5 million in the prior-year quarter, reflecting higher costs tied to the ALTO-207 PACE program. General and administrative (G&A) expense increased to $9.1 million from $4.4 million, largely due to higher headcount and related personnel costs.

On the balance sheet, the company reported cash, cash equivalents, and restricted cash of approximately $319.8 million as of September 30, 2026, up from roughly $177.0 million at the end of 2025. That position was strengthened by a $100.0 million gross financing completed in July 2026, which generated approximately $94.6 million in net proceeds. Management said the cash balance is expected to fund planned operations through 2030.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For a pre-revenue biotechnology name like Alto Neuroscience, the screener can help surface comparable clinical-stage companies, breakout candidates, and emerging trade ideas more efficiently than manual screening. Investors looking to monitor names such as ANRO alongside peers can explore the tool to identify opportunities that match their specific criteria.

Market Reaction and Investor Sentiment

Because Alto Neuroscience does not yet generate revenue, its stock typically reacts less to headline financials and more to pipeline milestones, financing activity, and management's commentary on trial timelines. The narrower-than-expected loss was a positive signal on near-term spending, but the wider year-over-year loss and higher R&D outlays underscore the cost of advancing multiple clinical programs simultaneously. Sentiment heading into and out of this report remains tied to the ALTO-207 program, which is in late-stage development for treatment-resistant depression, as well as upcoming readouts from ALTO-300 and ALTO-100. The company's extended cash runway through 2030 reduces near-term dilution risk, a factor that has historically influenced how clinical-stage biotech shares trade around earnings.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be focused on execution across Alto's clinical pipeline rather than quarterly income, given that the company remains pre-revenue. The most important near-term catalysts are the expected data readouts for ALTO-300 in major depressive disorder (MDD) in the first half of 2027 and for ALTO-100 in bipolar depression in mid-2027. The lead program, ALTO-207, is slated to deliver topline results from its PACE-1 Phase 2b trial in treatment-resistant depression in the second half of 2027.

Regulatory and operational milestones also bear watching. Alto plans to begin PACE-2, a Phase 3 adjunctive treatment-resistant depression trial, in early 2027 pending alignment with the U.S. Food and Drug Administration (FDA), and it expects to initiate PACE-3, a Phase 3 monotherapy trial, in the second half of 2027. Management has also flagged late 2026 and early 2027 as a window for ALTO-207 FDA interaction outcomes and Phase 1 topline data.

On the financial side, the key question is whether rising R&D and G&A spending stays within the runway management has guided toward. The company's roughly $319.8 million cash position, supplemented by the July 2026 financing, provides significant flexibility, but cost trends tied to expanding late-stage trials will remain a focus. Investors should monitor spending discipline, clinical enrollment progress, and any updates to trial timelines in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations